search
Back to results

RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration (TEMPURA)

Primary Purpose

Age Related Macular Degeneration

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
RBM-007 Injectable Solution
Sponsored by
Maturi, Raj K., M.D., P.C.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Age Related Macular Degeneration

Eligibility Criteria

50 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

• General Inclusion Criteria:

  1. Male or female patients, 50 years of age or older at baseline
  2. Patient has completed/signed an informed consent prior to any study-related procedures and is able to follow study instructions and likely to complete all required visits.

    • Ocular Inclusion Criteria:

  3. Best Corrected Visual Acuity (BCVA) 5 - 73 ETDRS letters (20/800-20/40 Snellen equivalent), inclusive, in study eye
  4. Presence of choroidal neovascularization secondary to AMD
  5. Clear ocular media and adequate pupil dilation to permit good quality photographic imaging.

Exclusion Criteria:

• General Exclusion Criteria:

  1. Females who are pregnant, nursing, planning a pregnancy or who are of childbearing potential not using a reliable method of contraception.
  2. History or current evidence of hypersensitivity to any components of the study medication or fluorescein, as assessed by the investigator.
  3. Participation in any investigational drug or device study within 30 days prior to baseline
  4. History or current evidence of a medical condition that may, in the opinion of the investigator, preclude the safe administration of study medication or affect the results of the study.

    • Ocular Exclusion Criteria:

  5. Active ocular or periocular infections, malignancy
  6. Aphakia
  7. History of pars plana vitrectomy in the study eye
  8. History of major ophthalmic surgery in the past 3 months in the study eye, or minor surgery in the past 30 days
  9. History of significant ocular disease other than exudative AMD that may confound results
  10. Uncontrolled glaucoma (defined as intraocular pressure >21mm Hg despite treatment with ocular hypotensive medications at baseline).

Sites / Locations

  • Midwest Eye Institute

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

RBM-007 Injectable Solution - 2.0 mg

Arm Description

Single intravitreal injection in study eye

Outcomes

Primary Outcome Measures

Macular Edema
Central subfield thickness on optical coherence tomography

Secondary Outcome Measures

Visual Acuity
Change from Baseline in Best Corrected Visual Acuity

Full Information

First Posted
May 17, 2021
Last Updated
March 20, 2023
Sponsor
Maturi, Raj K., M.D., P.C.
search

1. Study Identification

Unique Protocol Identification Number
NCT04895293
Brief Title
RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration
Acronym
TEMPURA
Official Title
Evaluation of RBM-007 in Subjects With Treatment naïve Exudative Age-related Macular Degeneration (AMD)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Completed
Study Start Date
June 15, 2021 (Actual)
Primary Completion Date
February 8, 2022 (Actual)
Study Completion Date
March 4, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Maturi, Raj K., M.D., P.C.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is a single-center, open label, 4-month study, designed to evaluate the safety and treatment efficacy of RBM-007 in patients with intraretinal or subretinal edema due to previously untreated neovascular AMD. Up to 5 subjects will be randomized to receive study medication. Study treatment will be administered by intravitreal injections.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Age Related Macular Degeneration

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Model Description
All subjects receive the study treatment
Masking
None (Open Label)
Allocation
N/A
Enrollment
5 (Actual)

8. Arms, Groups, and Interventions

Arm Title
RBM-007 Injectable Solution - 2.0 mg
Arm Type
Experimental
Arm Description
Single intravitreal injection in study eye
Intervention Type
Drug
Intervention Name(s)
RBM-007 Injectable Solution
Intervention Description
Sterile solution
Primary Outcome Measure Information:
Title
Macular Edema
Description
Central subfield thickness on optical coherence tomography
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Visual Acuity
Description
Change from Baseline in Best Corrected Visual Acuity
Time Frame
3 Months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: • General Inclusion Criteria: Male or female patients, 50 years of age or older at baseline Patient has completed/signed an informed consent prior to any study-related procedures and is able to follow study instructions and likely to complete all required visits. • Ocular Inclusion Criteria: Best Corrected Visual Acuity (BCVA) 5 - 73 ETDRS letters (20/800-20/40 Snellen equivalent), inclusive, in study eye Presence of choroidal neovascularization secondary to AMD Clear ocular media and adequate pupil dilation to permit good quality photographic imaging. Exclusion Criteria: • General Exclusion Criteria: Females who are pregnant, nursing, planning a pregnancy or who are of childbearing potential not using a reliable method of contraception. History or current evidence of hypersensitivity to any components of the study medication or fluorescein, as assessed by the investigator. Participation in any investigational drug or device study within 30 days prior to baseline History or current evidence of a medical condition that may, in the opinion of the investigator, preclude the safe administration of study medication or affect the results of the study. • Ocular Exclusion Criteria: Active ocular or periocular infections, malignancy Aphakia History of pars plana vitrectomy in the study eye History of major ophthalmic surgery in the past 3 months in the study eye, or minor surgery in the past 30 days History of significant ocular disease other than exudative AMD that may confound results Uncontrolled glaucoma (defined as intraocular pressure >21mm Hg despite treatment with ocular hypotensive medications at baseline).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Raj K. Maturi, M.D.
Organizational Affiliation
Midwest Eye Institute
Official's Role
Study Chair
Facility Information:
Facility Name
Midwest Eye Institute
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46290
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration

We'll reach out to this number within 24 hrs